Group 1: Market Outlook and Product Development - The active biological bone product is the first domestic bone filling product containing rhBMP-2, indicating high innovation potential. The market share for BMP products in bone repair materials is currently small but has significant growth potential [3]. - The company is enhancing its sales team's professional promotion capabilities to accelerate market expansion for the active biological bone product, with promotional activities progressing as expected this year [3]. Group 2: Oral Implant Industry and Competitive Landscape - Short-term demand for oral implants is relatively flat; however, long-term growth is expected due to factors like aging population and cost reductions from centralized procurement policies, which will increase implant penetration [3]. - The company aims to solidify its position in the oral repair membrane market by deepening cooperation with key terminals and stabilizing market share despite increasing competition and price wars [4]. Group 3: Procurement Projects and Market Share - As of now, 6 provincial and 2 inter-provincial alliances have initiated bulk procurement for the company's membrane products, covering a total of 24 provinces. The company has successfully bid in all provinces where procurement has occurred [4]. - Although bulk procurement has led to a decrease in membrane prices, it has also resulted in increased sales volume, maintaining stable market share [4]. Group 4: Stem Cell Project and Future Plans - The company is in the product process verification stage for its umbilical cord mesenchymal stem cell project, which will enhance its product offerings in the field of soft tissue repair and regenerative medicine [4]. - The company is actively planning to expand some products into overseas markets, aiming to achieve overseas revenue growth [5].

Market Overview - The Shanghai Composite Index closed at 3870.60 points, slightly above the six-month moving average, with a change of -0.12% [1] - The total trading volume of A-shares reached 25,483.12 billion yuan [1] Stocks Breaking the Six-Month Line - A total of 50 A-shares have surpassed the six-month moving average today, with notable stocks including Shanghai Construction, Yihualu, and Runjian Shares, showing divergence rates of 9.89%, 9.08%, and 9.07% respectively [1] - Stocks with smaller divergence rates that just crossed the six-month line include Zhuhai Port, Zhongzhou Special Materials, and Nanjing Chemical Fiber [1] Top Performers - Shanghai Construction (600170) saw a price increase of 9.96% with a turnover rate of 6.20% and a divergence rate of 9.89% [1] - Yihualu (300212) increased by 10.90% with a turnover rate of 12.71% and a divergence rate of 9.08% [1] - Runjian Shares (002929) rose by 9.99% with a turnover rate of 10.76% and a divergence rate of 9.07% [1] Additional Notable Stocks - Other significant gainers include Huafu Times (600169) with a 10.08% increase and a divergence rate of 7.82%, and Shang (002042) with a 10.06% increase and a divergence rate of 7.70% [1] - The stock of Fule New Materials (605488) rose by 10.01% with a divergence rate of 6.93% [1] Stocks with Lower Divergence Rates - Stocks like Zhonghuan Hailu (301040) and Baitong Energy (001376) showed increases of 1.91% and 1.55% respectively, with divergence rates of 1.09% and 1.00% [2] - Longyuan Construction (600491) increased by 1.91% with a divergence rate of 0.97% [2]

Core Viewpoint - Zhenghai Biological experienced a stock price increase of 2.18% on September 12, reaching 21.10 CNY per share, with a total market capitalization of 3.798 billion CNY [1] Financial Performance - For the first half of 2025, Zhenghai Biological reported operating revenue of 188 million CNY, a year-on-year decrease of 5.14%, and a net profit attributable to shareholders of 46.49 million CNY, down 45.97% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 617 million CNY, with 334 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Zhenghai Biological was 16,800, a decrease of 0.89% from the previous period, with an average of 10,704 circulating shares per shareholder, an increase of 0.90% [2] - The top ten circulating shareholders include notable funds such as Dongfanghong New Power Mixed A and Dongfanghong JD Big Data Mixed A, with changes in their holdings noted [3] Stock Performance - Year-to-date, Zhenghai Biological's stock price has increased by 1.22%, with a 3.58% rise over the last five trading days, a 4.70% decline over the last 20 days, and an 8.59% increase over the last 60 days [1]

（文章来源：每日经济新闻） 正海生物（300653.SZ）9月10日在投资者互动平台表示，活性生物骨用于填充由于创伤或手术造成的、 不影响骨结构稳定性的骨缺损。 每经AI快讯，有投资者在投资者互动平台提问：公司的产品海昱®活性生物骨对股骨头坏死有没有作 用？ ...

Core Viewpoint - The company is actively promoting its active biological bone products, with a focus on expanding market coverage and enhancing sales team capabilities [1] Group 1: Company Developments - The promotion and hospital entry of active biological bones are progressing smoothly and in line with expectations [1] - The company is strengthening the professional promotion capabilities of its sales team to further expand the hospital entry range and increase stable supply [1] - Current sales entry of active biological bones has not been affected by centralized procurement policies, although future impacts remain uncertain [1] Group 2: Market Outlook - The company will closely monitor centralized procurement policies and industry dynamics to adapt to potential market changes [1]

Core Viewpoint - Zhenghai Biological announced on September 9 that its intrauterine repair membrane product is primarily used in the field of endometrial repair, and the company is currently conducting registration-related work for the product, which will expand the clinical application areas of its soft tissue repair material series, providing significant support for seeking new business growth points [1] Group 1 - The intrauterine repair membrane product is aimed at the endometrial repair field [1] - The company is in the process of registration for this product [1] - The expansion of clinical application areas will enhance the company's regenerative repair product lineup [1]

Core Viewpoint - Zhenghai Biological announced the development of a calcium-silicate-based bio-ceramic bone repair material, which promotes osteogenic differentiation and vascularization, aiding in the repair and regeneration of alveolar bone [1] Group 1: Product Details - The calcium-silicate bio-ceramic bone repair material is the first of its kind in China, utilizing 3D printing technology and high-temperature sintering to create a porous structure similar to autologous bone [1] - This product offers a superior osteogenic environment for tissue and has the potential for customized production to meet patient needs [1] Group 2: Regulatory Timeline - The company expects to obtain the registration certificate for the product by the end of 2025 [1]

Core Viewpoint - The company is facing intensified competition and demand fluctuations in the private market for its oral repair membrane products, while maintaining a stable sales structure in the public market [1] Group 1: Market Challenges - The company reports that the competitive landscape in the private market is becoming increasingly aggressive, leading to a price war [1] - Demand fluctuations in the private market are posing additional pressures and challenges for the company [1] Group 2: Strategic Responses - The company aims to solidify its competitive position in the implant sector by executing a precise marketing strategy [1] - There is a focus on strengthening collaboration with leading end-users to stabilize market share coverage [1] - The company plans to accelerate the launch and promotion of new products, leveraging the combined capabilities of its membrane powder product line to enhance market competitiveness [1]

Group 1 - The company announced that it will actively respond to the upcoming centralized procurement project for medical consumables related to hard brain (spinal) membrane patches, as per the notice issued by Tianjin City in June 2024 [1] - The company's series of membrane products have successfully won bids in all provinces where centralized procurement has been implemented, indicating a stable market share despite price reductions [1] - Overall, the centralized procurement has led to a decrease in the selling price of the company's membrane products, which has correspondingly increased sales volume [1]

关于取得医疗器械注册变更文件的公告 证券代码：300653 证券简称：正海生物 公告编号：2025-039 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）于近日取得由国家药 品监督管理局颁发的 1 项《医疗器械变更注册（备案）文件》，公司完成产品"硬 脑（脊）膜补片"的产品技术要求及规格型号相关内容的变更，现将相关情况公 告如下： 一、该医疗器械的基本信息 | 产品名称 | 注册证编号 | | | | | 注册证有效期 注册分类 适用范围 | | --- | --- | --- | --- | --- | --- | --- | | 硬脑（脊） | 国械注准 | 年 12 23 | | 月 | 日至 | 第三类医疗 用于硬脑（脊）膜缺损的修 2022 | | 膜补片 | 20223131789 | 12 月 22 | 年 | | 日 | 2027 器械 复。 | 变更内容： 1、增加产品的规格型号。 2、对产品技术要求相关内容进行变更。 上述变更文件与"国械注准 20223131789"注册证共同使用。 烟台正 ...